Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The dose-escalation study is taking place in the US
The specialist in human disease models said it is in talks with pharmaceutical companies over further deals
Drug trials are divided into four phases, though a drug only has to successfully negotiate three of these four stages to receive sign-off by the regulatory bodies
The act of securing of licensing deals and partnerships is such an important value inflexion point for smaller drug developers, it warrants a more detailed write up of its own
It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
Underlying sales growth has been maintained at 10%
The pioneer of the human microbiome, the bacteria that inhabit the gut and skin, will work with CTC which will distribute weight management product SlimBiome in the Philippines, Vietnam, Indonesia and Colombia
LogicBio is a specialist in genome editing that is developing drugs for rare diseases
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.